The UK government has secured access to a further 90 million doses of potential coronavirus vaccines.
The new agreements, on top of earlier deals, mean the UK now has access to six different Covid-19 vaccine candidates in development.
The latest are being developed by US biotech company Novavax and pharmaceutical business Janssen, which is headquartered in Belgium and owned by Johnson & Johnson.
Under the in-principle agreements, Janssen Pharmaceutica will supply Britain with 30 million doses of its candidate. Ministers have also agreed to co-fund a global clinical study of its vaccine.
Alongside Janssen's candidate, the UK has also secured 60 million doses of the Novavax vaccine, with it supporting a Phase 3 clinical trial with the National Institute for Health Research (NIHR).
Both deals bring the UK’s total number of secured doses to 362 million - enough for five doses per person.
Despite the scale of the government’s potential stockpile, Kate Bingham, chair of the government’s Vaccines Taskforce, warned that it was still not known if any of the vaccines would be effective.
Speaking to ITV’s Good Morning Britain on Friday, she said: “The issue is we don’t know which, if any, of these vaccines may work, because there have been no vaccines against any human coronavirus."
“So what we’re doing is we’ve chosen six of the most promising vaccines across four different vaccine types and we’re hoping that one of those will work," she added.
Ms Bingham said that it is unlikely all six of the vaccines will work.
"The reality is that most will fail and we want to be sure that if any one is shown to be effective and safe that we have rights to it."
She told Good Morning Britain she was “reasonably confident” of a vaccine being found that will reduce the severity of coronavirus symptoms and reduce deaths.
The government’s latest agreement follows on from 90 million doses in the pipeline under deals with an alliance between the pharmaceutical giants BioNtech and Pfizer, as well as the firm Valneva.
Some 100 million doses of vaccine could come from a vaccine being developed by Oxford University in partnership with AstraZeneca.
While a deal has been struck for 60 million doses of GlaxoSmithKline (GSK) and Sanofi Pasteur’s potential Covid-19 vaccine.
The deals cover four different classes: adenoviral vaccines, mRNA vaccines, inactivated whole virus vaccines and protein adjuvant vaccines.
Business Secretary Alok Sharma said: “Today’s agreements will not only benefit people in the UK, but will ensure fair and equitable access of a vaccine around the world, potentially protecting hundreds of millions of lives."
He added: "While we are doing everything we can to ensure the British people get access to a successful vaccine as soon as possible, nobody is safe until we are all safe, so global cooperation is absolutely critical if we are to defeat this virus once and for all.”
The Janssen vaccine, which is being made available on a not-for-profit basis, is expected to begin the next phase of clinical trials later this year and will look at whether two doses can provide long-term protection from coronavirus.
Meanwhile, Novavax plans to make some of its vaccine at Fujifilm Diosynth Biotechnologies’s facilities in Billingham, Stockton-on-Tees once it is available.
The government said that if the Novavax and Janssen vaccines are proven safe and successful in clinical trials they could be delivered to the UK in mid-2021.
The vaccines would first be given to priority groups such as front-line health workers, those with serious diseases, the elderly and ethnic minorities.